Global Chronic Kidney Disease Drugs Market – Size, Share and Forecast (2019-2026)

SKU: DPH23 | Published On: 2019-04-09 | Available Formats

Chronic Kidney Disease Drugs Market

  • The global chronic kidney disease drugs market is expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.
  • Chronic kidney disease, also known as chronic kidney failure, describes the gradual loss of kidney function. Kidneys filter the wastes and excess fluids from blood, which are then excreted in the urine.
  • However, individuals with chronic kidney disease kidneys cannot perform their natural kidney functions, and dangerous levels of fluid, electrolytes and wastes build up in their body.
  • The symptoms and signs of chronic kidney disease are not apparent until kidney function becomes significantly impaired.
  • Diseases and conditions that cause chronic kidney disease include diabetes, high blood pressure, glomerulonephritis (inflammation of the kidney’s filtering units), interstitial nephritis (inflammation of the kidney’s tubules and surrounding structures) and polycystic kidney disease.

 

Chronic Kidney Disease Market Dynamics

  • The global chronic kidney disease drugs market’s primary driver is the increasing prevalence of chronic kidney disease among the population globally. Other
  • essential factors propelling the growth of this drugs market is the rise of the aging population, who due to their poor immunity are more susceptible to various diseases such as cardiovascular diseases and diabetes. These diseases increase the risk of chronic kidney disease.
  • Continuous requirement for the drugs to treat the patients along with easy availability is expected to boost the chronic kidney disease drugs market. According to the Centers for Disease Control & Prevention (CDC), 2017, approximately 15% of the adults in the U.S. have chronic kidney disease.
  • Additionally, the increasing awareness and R&D by government organizations and manufactures about chronic kidney diseases foster the growth of the drugs market.
  • However, delayed diagnosis of the chronic kidney disease due to vague symptoms, the inclination to generic medication options and patent expiry of drugs are expected to limit the growth of the constant kidney disease drugs market.

 

Chronic Kidney Market Segmentation Analysis

  • By Drug class, the market is segmented into ACE inhibitors, calcium channel blockers, B- blockers, diuretics, erythropoiesis-stimulating agents (ESAS), and others. Calcium channel blockers hold the most significant market share as they are commonly used the treatment of chronic kidney diseases.
  • Calcium channel blockers prevent, treat or improve symptoms in a variety of conditions, such as high blood pressure and coronary artery disease, which can increase the risk of chronic kidney diseases. Presently, dominant calcium channel blockers utilized across the world are phenyl alkyl amines (verapamil), benzothiazepines (diltiazem), and dihydropyridines (nifedipine and amlodipine).
  • By the distribution channel, the chronic kidney disease drugs market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies dominate the market. However, online pharmacies share is expected to be the fastest growing share.
  • It is mainly due to secure transactions that are provided by online retailers as in most cases of chronic kidney disease treatments the medication is needed on a regular base, easy availability of the drug are expected to boost the share.

 

Global Chronic Kidney Market Geographical Share

  • North America dominates this regional market owing it to the high prevalence of diabetes and the alarming growth in the obese population.
  • The presence of a state-of-art medical and healthcare industry is also expected to drive this regional market. According to the Centers for Disease Control and Prevention (CDC), more than 26 million Americans are affected by chronic kidney diseases.
  • Increasing the awareness of chronic kidney diseases by government organizations are expected to propel the market further. For instance, in 2018, the American Kidney Fund launched a new kidney disease education portal called ‘CKD Central,’ that will provide information and resources on chronic kidney disease (CKD). In the same year, Fresenius Medical North America (FMCNA) contributed 40,000 USD to Kidney School, the world’s most extensive education program for people with chronic kidney disease.
  • Europe holds the second largest regional market is owing to the increasing pool of patients who have kidney cancer in the region. Europe is likely to offer the most favorable growth opportunities to crucial market players.
  • Asia-Pacific region is expected to project the most market growth owing it to the high prevalence of diabetes in the
  • area, developing healthcare infrastructure, favorable government norms, and growing awareness of chronic kidney diseases.
  • For instance, in March 2018, the Indian Medical Association launched a chronic kidney disease prevention project to control the ever-increasing epidemic of chronic kidney disease in India.

 

Chronic Kidney Market Competitive Trends

  • Key players are adopting strategies such as mergers and acquisitions, product launches, partnerships, and regional expansion to stand out as strong competitors in the market.
  • Dec. 2018, Akebia Therapeutics and Keryx Biopharmaceuticals announced the successful completion of their previously announced merger.
  • The merger aim is to create a fully integrated renal company that has the potential to set new standards of care for patients with kidney disease
  • Dec 2018, China became the first country to approve a new anemia drug for chronic kidney disease from AstraZeneca and fibrinogen, before the United States or Europe. FibroGen sponsored the development and registration of roxadustat in China, while AstraZeneca is responsible for marketing the medicine.
  • Nov 2018, GlaxoSmithKline strategic collaboration deal with Japanese company Kyowa Hakko Kirin for the future commercialization of its late-stage candidate, daprodustat, in Japan.
  • Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is currently being evaluated in phase III studies for the treatment of anemia associated with chronic kidney disease
  • June 2018, The US Food and Drug Administration approved Mircera for pediatric use. Mircera is a long-acting erythropoiesis-stimulating agent (ESA) of Vifor Pharma.
  • Sept 2017, Roche and Vifor Pharma extended an agreement on the marketing of Mircera in the USA. The deal provides Vifor with access to add volume for Mircera for the US market. The companies signed a commercialization deal in 2015 for the drug, which is approved in the USA and Europe for the treatment of anemia in certain chronic kidney disease patients.
  • Feb. 2017, Vifor Pharma, a company of the Galenica Group, and ChemoCentryx entered a licensing deal of over 100 million USD. Vifor Pharma gained rights to commercialize ChemoCentryx’s avacopan (CCX168) in Asia, including Japan and the Middle-East.
  • ChemoCentryx retains all rights in the United States and China. Avacopan is an orally-administered drug currently in Phase III development for rare renal diseases.
  • Some of the key players in the chronic kidney disease drugs market are F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, and Sanofi S.A.

 

Why Purchase the Report?

  • Visualize the composition of the global chronic kidney disease drugs market across each indication, in terms of type and treatment options, highlighting the key commercial assets and players.
  • Identify business opportunities in global chronic kidney disease drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global constant kidney disease drugs market – level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the principal products of all major market players.

 

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Global Chronic Kidney Disease Market

Section 1. Chronic Kidney Disease Market - Methodology and Scope

1.1 Research methodology

1.2 Research Objective and Scope of the Report

Section 2. Chronic Kidney Disease Market - Industry Trends

Section 3. Chronic Kidney Disease Market Outlook

3.1 Market Snippet by Drug class

3.2 Market Snippet by Distribution Channel

3.3 Market Snippet by Region

3.4 DataM CLO Scenario

Section 4. Chronic Kidney Disease Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunity

4.4 Impact Analysis

Section 5. Chronic Kidney Disease Market - Industry Analysis

5.1 Porter’s Five Forces Analysis

5.2 Supply Chain Analysis

5.3 Pricing Analysis

5.4 Regulatory Analysis

5.5 Patent Analysis

Section 6. Chronic Kidney Disease Market Segmentation Analysis – By Drug class

6.1 ACE Inhibitors

6.2 Calcium Channel Blockers

6.3 B- Blockers

6.4 Diuretics

6.5 Erythropoiesis-Stimulating Agents (ESAS)

6.6 Others

Section 7. Chronic Kidney Disease Market Segmentation Analysis – By Distribution Channel

7.1 Hospital Pharmacies

7.2 Retail Pharmacies

7.3 Online Pharmacies

7.4 Others

Section 8. Chronic Kidney Disease Market - Regional, Country-level Analysis

8.1 North America

8.1.1 U.S.

8.1.2 Canada

8.1.3 Mexico

8.2 Europe

8.2.1 Germany

8.2.2 U.K.

8.2.3 France

8.2.4 Italy

8.2.5 Spain

8.2.6 Rest of Europe

8.3 South America

8.3.1 Brazil

8.3.2 Argentina

8.3.3 Rest of South America

8.4 Asia Pacific

8.4.1 China

8.4.2 India

8.4.3 Japan

8.4.4 Australia

8.4.5 Rest of Asia Pacific

8.5 Middle East & Africa

Section 9. Chronic Kidney Disease Market - Competitive Analysis

9.1 Competitive Scenario

9.2 Competitor Strategy Analysis

9.3 Comparative Product Portfolio Analysis

9.4 Market Positioning/Share Analysis

9.5 Mergers and Acquisitions Analysis

Section 10. Chronic Kidney Disease Market - Company Profiles

10.1 Pfizer Inc.

10.2 Sanofi S.A.

10.3 F. Hoffmann-La Roche Ltd.

10.4 Teva Pharmaceutical Industries Ltd.

10.5 AstraZeneca Plc.

10.6 Kissei Pharmaceutical Co

10.7 AbbVie Inc.

10.8 GlaxoSmithKline Plc

10.9 Amgen Inc.

10.10 Keryx Biopharmaceuticals, Inc.

Section 11. Chronic Kidney Disease Drugs Market – Premium Insights

Section 12. Chronic Kidney Disease Drugs Market – DataM

12.1 Appendix

12.2 About Us and Services

12.3 Contact Us

Buy This Report



To get the free report sample tailored to your requirements

Could not find what you need?

Quick Fact: 7 of 10 customers Tailor their reports

DMI Cognizance Expertise

Massive Repository

10-year historic data for 1000+ markets

Association Networks

Ground-Zero understanding of the market with inputs from relevant industry association members

First Hand Understanding

Tailored interviews with manufacturers, buyers, sellers, distributers and retailers for five-frame understanding of the market

360 Web Research

Analysis of publicly available white label papers, news announcements, press releases, financial reports and reliable paid consulting data

Star Expert Review

7-step data formulation for market analysis and forecasts, under thorough scrutiny of industry-specific consultants with over 20+ years of expertise

INSTANT DELIVERY - 20% OFF

Copyright © 2019 DataM Intelligence. All Rights Reserved

Designed and Developed by -Montaigne Labs